Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $27.7 million.

  • Spyre Therapeutics' Accumulated Expenses rose 81.15% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 81.15%. This contributed to the annual value of $27.7 million for FY2024, which is 111.41% up from last year.
  • As of FY2024, Spyre Therapeutics' Accumulated Expenses stood at $27.7 million, which was up 111.41% from $13.1 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Accumulated Expenses ranged from a high of $27.7 million in FY2024 and a low of $12.8 million during FY2022.
  • In the last 3 years, Spyre Therapeutics' Accumulated Expenses had a median value of $13.1 million in 2023 and averaged $17.9 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first declined by 8.50% in 2022, then soared by 111.41% in 2024.
  • Spyre Therapeutics' Accumulated Expenses (Yearly) stood at $13.9 million in 2020, then grew by 1.15% to $14.0 million in 2021, then fell by 8.50% to $12.8 million in 2022, then rose by 2.11% to $13.1 million in 2023, then skyrocketed by 111.41% to $27.7 million in 2024.